Clinical Study to Evaluate the Effects of the Complement C5 Inhibitor Ravulizumab on Serum Neurofilament Light Chain (sNfL) and Glial Fibrillary Acidic Protein (sGFAP) Levels in Patients With Aquaporin-4-Positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD)

NCT06903130 · clinicaltrials.gov ↗
NOT_YET_RECRUITING
Status
40
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

National and Kapodistrian University of Athens